Understanding Androgen Receptor Pathway Inhibitors in Metastatic Castration-Sensitive Prostate Cancer

Experts unpack evolving mCSPC care, from ARPIs and chemo to PARP and PSMA advances, plus guideline-driven, personalized therapy choices.

Panelists explore how clinicians differentiate among available androgen receptor pathway inhibitor (ARPI)-based doublet therapies for patients with metastatic castration-sensitive prostate cancer (mCSPC).

In “Risk Stratification and Treatment Intensification Strategies in mCSPC,” our panel explores how clinicians use clinical, molecular, and genomic risk factors to personalize treatment decisions for patients with metastatic castration-sensitive prostate cancer (mCSPC). The expert faculty discuss how disease volume, timing of metastasis, tumor burden, PSA kinetics, and patient comorbidities influence risk stratification and guide the selection of doublet, triplet, and metastasis-directed treatment approaches.

This episode, titled “Emerging Treatment Strategies in mCSPC,” features panelists discussing the rapidly evolving treatment landscape in metastatic castration-sensitive prostate cancer (mCSPC) and the growing number of therapeutic approaches being incorporated alongside androgen deprivation therapy (ADT) and androgen receptor pathway inhibitors (ARPIs).

As treatment options continue to expand, the expert faculty discuss where current evidence remains limited and identify key areas for future research that may further refine treatment selection and disease management.

As the treatment landscape continues to evolve, the expert faculty discuss how real-world considerations, including treatment access, insurance coverage, and patient costs, can significantly influence therapeutic decisions, sometimes as much as the clinical evidence itself.

As real-world evidence (RWE) becomes increasingly integrated into oncology research, the expert faculty discuss both the strengths and limitations of these analyses and how they complement findings from prospective clinical trials.

The expert faculty discuss the opportunities and limitations of comparative analyses, highlighting the importance of understanding potential biases and patient-level factors when applying real-world findings to clinical practice.

The expert faculty emphasize that while ARPI-based therapies have significantly improved outcomes, successful treatment requires balancing clinical benefit with quality of life and long-term tolerability.

The expert faculty examine how access barriers, insurance coverage, and financial considerations can shape treatment decisions, often requiring clinicians to balance clinical preferences with practical realities.

The expert faculty discuss how the expanding treatment landscape continues to evolve while highlighting the practical challenges associated with ensuring patients remain on therapy over time.

The expert faculty highlight the importance of combining clinical evaluation, laboratory testing, and imaging to guide management decisions and identify disease progression as early as possible.